Human RANTES-CCL5 Recombinant

/, CCL chemokines/Human RANTES-CCL5 Recombinant

Human RANTES-CCL5 Recombinant


accession P13501

Source Optimized DNA sequence encoding Human Rantes/CCL5 mature chain was expressed in Escherichia Coli.
Molecular weight Native human RANTES/CCL5 isgenerated by the proteolytic removal of the signal peptideand propeptide, the molecule has a calculated molecular mass of approximately8 kDa. Recombinant RANTES/CCL5is a monomer protein consisting of amino acid residue subunits andmigrates as an approximately8 kDa protein under non-reducing and reducing conditions in SDS-PAGE.
Purity >98%, as determined by SDS-PAGE and HPLC
Biological Activity Determined by its ability to chemoattract human blood monocytes using a concentration range of.0-10.0 ng/ml.

Endotoxin Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg).
Presentation Recombinant Rantes/CCL5was lyophilized from a.2 μm filtered PBS solution.
Reconstitution A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers.
Storage The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.

Interactor P01730 CD4_HUMAN
Interactor P15172
Interactor P32246
Interactor P51681
Interactor P32302
Interactor P49682
Interactor P51677
Biological Process Chemotaxis
Biological Process Inflammatory-response
Molecular function Cytokine


CCL5/RANTES or CX3CL1/Fractalkine binding to US28 triggers calcium release in HCMV infected smooth muscle but not glioblastoma cells.

  • At 48 hpi, cells were labeled with Fluo-4 AM and stimulated with 10 nM CCL5/RANTES (top panels) or 10 nM CX3CL1/Fractalkine (bottom panels).

GLP-1(9-36) inhibits chemokine-induced migration of isolated human CD4-positive lymphocytes.

  • A. and B.: Cells were pretreated with GLP-1(9-36) for 30 minutes at concentrations indicated before migration experiments using SDF-1 (100 ng/mL) or RANTES (100 ng/mL) were performed for three hours in the modified Boyden chamber.

Effects of CoCl2, an NF-κB inhibitor, and HO-1 RNA interference on TNF-α/IFN-γ-induced cytokine production.

  • The production of RANTES and MCP-1 was analyzed in the supernatants of HK-2 cells using ELISA.

Interaction of CXCL447–70 and CXCL4L147–70 with CCL5 Changes in the expression of murine (mu) CCL5 within the tumor microenvironment were evaluated in vehicle (CO)-, CXCL447–70- and CXCL4L147–70-treated MDA-MB-231 tumors by qPCR (A).

recombinant human CCL5
  • In order to further evaluate a possible interaction between CCL5 and the administered peptides, binding of biotinylated CXCL447–70 or CXCL4L147–70 to human CCL5-coated plates was quantified , whereas functional synergy was investigated by evaluating chemotaxis of monocytic cells .